Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis
The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.
1. A pharmaceutical composition comprising a compound represented by Chemical Formula 1:
wherein
R 1 is selected from the group consisting of
naphthalyl, and naphthalyl substituted with C 1 -C 6 alkyl;
R 2 is selected from the group consisting of
hydroxynaphthalyl, and 4-(2-hydroxyethyl)cyclohexyl;
A 1 is C 1 -C 6 alkyl or phenyl; and
B 1 , B 2 , B 4 , and B 5 are each independently selected from the group consisting of H—, halo, hydroxyl, nitro, and C 1 -C 6 alkyl, and B 3 is selected from the group consisting of H—, halo hydroxyl, and C 1 -C 6 alkyl.
2. The pharmaceutical composition of claim 1 , wherein A 1 is methyl, ethyl, phenyl, or tert-butyl.
3. The pharmaceutical composition of claim 1 , wherein B 1 is H—, chloro, fluoro, hydroxyl, nitro, or methyl.
4. The pharmaceutical composition of claim 1 , wherein the hydroxy naphthalyl is 7-hydroxy naphthalyl.
5. The pharmaceutical composition of claim 1 , wherein the compound is selected from the group consisting of:
6. The pharmaceutical composition of claim 5 , wherein the composition is selected from the group consisting of the compounds represented by Chemical Formulas 5, 6, 12, 17, 21, 23, and 24.
7. A method of treating a disease or disorder selected from the group consisting of cancer, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma and, proliferative retinopathy, the method comprising:
administering an appropriate dose of the pharmaceutical composition of claim 1 to a subject in need thereof.
8. The method of claim 7 , wherein the disease or disorder is a cancer, diabetic retinopathy, or proliferative retinopathy.
9. The method of claim 8 , wherein the proliferative retinopathy is age-related macular degeneration.
10. A compound selected from the group consisting of compounds represented by Chemical Formulas 2, 3, 4, 11, 12, 13, 15, 16, 17, 18, 19, 20, 22, 23, 24, 26, and 29: